

Curis, Inc. Investor Relations Department 4 Maguire Road Lexington, MA 02421 United States

Visit IR website ☐ Sign-up for email alerts ☐

2.07
2:51 PM ET Jul 24, 2017
0.08 † (4.020%)
1.98 - 2.10
1.56 - 3.72
200,634

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Curis is a drug development company that is committed to leveraging its innovative signaling pathway drug technologies to seek to create new targeted small molecule drug candidates for cancer. In expanding its drug development efforts in the field of cancer through its proprietary targeted cancer programs, Curis is building upon its previous experiences in targeting signaling pathways for the development of next generation targeted cancer therapies. For more information, visit Curis' website at www.curis.com.... (more)

Stock Performance



Press Releases [View all]

Jul 5, 2017

Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Jun 1, 2017

<u>Curis to Present at the Jefferies Healthcare</u> Conference

May 25, 2017

Curis Announces Presentations Related to CA-170 and CUDC-907 at 2017 ASCO Annual Meeting

May 4, 2017

<u>Curis Reports First Quarter 2017 Financial</u> <u>Results</u>

Apr 28, 2017

Curis to Release First Quarter 2017 Financial Results and Hold Conference Call on May 4, 2017

Financials [View all]

First Quarter Financial Results

Mar 9, 2017

Annual Report (10-K)

Apr 4, 2017

Proxy Statement (DEF 14A)

May 4, 2017

Quarterly Report (10-Q)

Nov 3, 2016

Quarterly Report (10-Q)

Aug 4, 2016

Quarterly Report (10-Q)